SingleApprovedRegulatory LabelHigh confidenceSourced

SS-31 / Elamipretide

A mitochondria-targeting peptide approved in the US as Forzinity for a narrow Barth-syndrome population. The authorised formulation and indication do not validate generic SS-31 products.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

Two community-provenance subcutaneous lines for SS-31 (elamipretide) - a protocol author's short daily cycle and a lower everyday band. Community reports only, not the Forzinity label or a trial-verified schedule.

Evidence source

Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported cycle phases

Select a point for its calculation examples

Short cycle (10-20 days)
10 mg
A protocol author describes about 10 mg daily for 10-20 days, then a break before switching to MOTS-C.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 10 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator

Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface — One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.

BAC water selected

1 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

U-100 draw20 U

20-30 U reference band

1 mL BAC

20 units

resulting U-100 draw

Concentration: 50 mg/mL
BAC added: 1 mL

Shown in the diagram. Closest of these examples to 25 units.

2 mL BAC

40 units

resulting U-100 draw

Concentration: 25 mg/mL
BAC added: 2 mL

3 mL BAC

60 units

resulting U-100 draw

Concentration: 16.667 mg/mL
BAC added: 3 mL

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Regulatory LabelSubcutaneousOnce daily

Adult and pediatric patients with Barth syndrome weighing at least 30 kg

40 mg subcutaneously once daily using the authorised Forzinity formulation

This US accelerated-approval schedule is indication- and formulation-specific. The label requires dose reduction for adults with severe renal impairment and does not establish equivalence to research vials.

View source

Human StudySubcutaneousOnce daily

Adults with genetically confirmed primary mitochondrial myopathy

40 mg subcutaneously once daily for 24 weeks

MMPOWER-3 was a monitored phase 3 trial and did not improve its primary walking-distance or fatigue endpoints.

View source

Human StudySubcutaneousOnce daily

Adults with primary mitochondrial myopathy

40 mg subcutaneously once daily for four weeks in a crossover study

This small phase 2 study generated signals that were not confirmed on the phase 3 primary endpoints.

View source

Community GuideSubcutaneous in reportsDaily to intermittent; no consensus

online research community protocols

The spotlight states 1-5 mg subcutaneously daily or several times weekly, while reported stacks span 0.5-16 mg daily and 25-50 mg pulse schedules

The archive ranges exceed 100-fold and are not comparable with the indication-specific Forzinity label. They are practitioner and community protocols, not a consensus; raw/peptide-education/pe-ss31.md:18-29 and raw/peptide-education/pe-mitochondrial-protocols.md:20-54.

View source

Community GuideSubcutaneous in reportsDaily for 10-20 day cycles; intermittent variants reported

authenticated research-forum (Peppys) mitochondrial-stack reports

A protocol author describes about 10 mg subcutaneously daily for 10-20 days then a break before MOTS-C; the common real-world band is 3-5 mg daily, with reports spanning 0.5-16 mg daily up to 25-50 mg pulse schedules and doubted 200-250 mcg microdoses

Forum provenance from an authenticated archive with usernames omitted. SS-31 (elamipretide) is used subcutaneously, almost always as the first leg of a mitochondrial stack into MOTS-C. Quantities conflict by more than 100-fold, human data is described as thin, and these are community protocols rather than a consensus or the indication-specific Forzinity label.

View source

Evidence summary

A mitochondria-targeting peptide now authorised in the US as Forzinity for eligible patients with Barth syndrome weighing at least 30 kg. Approval is accelerated and indication-specific; earlier mitochondrial-myopathy trials remain separate evidence.

Protocol basis

The protocol is anchored first to the authorised Forzinity formulation and label, then to matched elamipretide trials. Generic products labelled SS-31 are not established as equivalent to the approved medicine.

Community provenance (Peppys)

An authenticated research-forum archive records SS-31 (elamipretide) used subcutaneously, almost always as the first leg of a mitochondrial stack into MOTS-C. A protocol author describes roughly 10 mg daily for 10-20 days followed by a break, while the common everyday band is about 3-5 mg daily; reported quantities range more than 100-fold, from doubted 200-250 mcg microdoses up to 25-50 mg pulse schedules. The archive stresses thin human data and keeps these community protocols separate from the indication-specific Forzinity label. Usernames and post numbers are omitted. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.

What remains uncertain

Confirmatory clinical benefit under accelerated approval, generalisability beyond Barth syndrome and equivalence to products labelled only SS-31 remain unresolved.

Warnings and contraindications

Forzinity is authorised only for eligible patients with Barth syndrome weighing at least 30 kg under accelerated approval.

Products labelled only SS-31 are not established as equivalent to the authorised 80 mg/mL elamipretide formulation.

Injection-site reactions were common in the phase 3 mitochondrial myopathy trial.

A trial schedule is not evidence for general wellness or performance use.

Contraindications reported by the source

Serious hypersensitivity to elamipretide or a formulation ingredient

Organised research bench with labelled storage tray, vial rack, notebook and thermometer — A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.